Cognition Therapeutics Inc (CGTX) has a current Price-to-Book (P/B) ratio of 3.55. Compared to its 3-year average P/B ratio of 2.93, the current P/B ratio is approximately 21.32% higher. Relative to its 5-year average P/B ratio of 2.31, the current P/B ratio is about 53.54% higher. Cognition Therapeutics Inc (CGTX) has a Forward Free Cash Flow (FCF) yield of approximately -22.76%. Compared to its 3-year average FCF yield of -61.21%, the current FCF yield is approximately -62.81% lower. Relative to its 5-year average FCF yield of -45.61%, the current FCF yield is about -50.10% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CGTX competitors is 278.01, providing a benchmark for relative valuation. Cognition Therapeutics Inc Corp (CGTX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CGTX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CGTX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CGTX currently overvalued or undervalued?

What is Cognition Therapeutics Inc (CGTX) fair value?

CGTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Cognition Therapeutics Inc (CGTX) is between to according to relative valuation method.

How does CGTX's valuation metrics compare to the industry average?

The average P/S ratio for CGTX's competitors is 278.01, providing a benchmark for relative valuation. Cognition Therapeutics Inc Corp (CGTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Cognition Therapeutics Inc (CGTX) as of Mar 03 2026?

As of Mar 03 2026, Cognition Therapeutics Inc (CGTX) has a P/B ratio of 3.55. This indicates that the market values CGTX at 3.55 times its book value.

What is the current FCF Yield for Cognition Therapeutics Inc (CGTX) as of Mar 03 2026?

As of Mar 03 2026, Cognition Therapeutics Inc (CGTX) has a FCF Yield of -22.76%. This means that for every dollar of Cognition Therapeutics Inc's market capitalization, the company generates -22.76 cents in free cash flow.

What is the current Forward P/E ratio for Cognition Therapeutics Inc (CGTX) as of Mar 03 2026?

As of Mar 03 2026, Cognition Therapeutics Inc (CGTX) has a Forward P/E ratio of -5.64. This means the market is willing to pay $-5.64 for every dollar of Cognition Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Cognition Therapeutics Inc (CGTX) as of Mar 03 2026?

As of Mar 03 2026, Cognition Therapeutics Inc (CGTX) has a Forward P/S ratio of 0.00. This means the market is valuing CGTX at $0.00 for every dollar of expected revenue over the next 12 months.

CGTX Valuation